Gary Price: Living the Best Life Possible with Metastatic Bladder Cancer

 

​​

Age: 59
Willis, Texas

Almost three years after I was first diagnosed with bladder cancer, I learned that it had metastasized. Aggressive chemotherapy did not stop the cancer, and I was told I had just months to live. But then I took part in a clinical trial testing a new medicine, erdafitinib (Balversa). Erdafitinib has stopped the tumor from growing for three years now, and although I have some serious side effects from the medicine, I am making the best of my life.

It all started in the summer of 2013, when I noticed some blood in my urine. The first time it happened was startling, but I didn’t worry too much. Then it happened again and again, so I went to my primary care physician who recommended a series of tests. An ultrasound showed that my right kidney was extremely enlarged, which led to an MRI that showed a mass in my bladder. Finally, my local urologist did a cystoscopy, and I was told that I had bladder cancer.

It was very traumatic to hear the words, “you have cancer.” I immediately wondered if it was a death sentence, but the urologist reassured me that the cancer had not spread out of the bladder and that they could treat it.

Days after the diagnosis, I had surgery to remove the tumor. It was as big as a billiard ball and blocking the tube from my right kidney to my bladder, which is why the kidney was so enlarged.

After the surgery, I had several treatments with BCG, but they did not keep me free of cancer. Over the next year or so, I had surgery five or six times to remove papillary-type tumors that kept growing in my bladder. My oncologist told me that these were not as aggressive as the first tumor that was removed but he recommended that I transfer my treatment to The University of Texas MD Anderson Cancer Center.

The medical team there recommended more extensive surgery, and in June 2015 I had a 15-hour surgery to remove my bladder, my right kidney, which had been so badly damaged that it was no longer functioning, my right ureter [the tube connecting the kidney and bladder], and my prostate.

The surgery was life changing. For example, I have an ostomy bag that I deal with every day, but it was something that I had to do to give myself the best chance of beating the cancer.

I was cancer free for just under a year. In April 2016, my routine follow-up scans showed a nodule in a scar that I had from where a drain from my kidney had been placed. A biopsy showed that it was the bladder cancer. I had metastatic disease.

I spent three days in the hospital receiving a very aggressive chemotherapy treatment, but that didn’t stop the tumor from growing. I needed something different.

The oncologist checked a sample of my tumor and told me it had an alteration in a certain receptor, the FGFR3 receptor. She also said that she was involved in a clinical trial testing a new medicine for people with cancer who have alteration in this receptor. I felt that it was my best choice and I have been taking erdafitinib ever since.

I am not cancer free, but the erdafitinib has controlled the growth of the tumor. It remains the size of a pea.

The erdafitinib does not make me sick like standard chemotherapy does for many people, but I have had to learn to live with some serious side effects. I have hand-foot syndrome, which means my hands and feet hurt severely all the time and it is hard to use my hands, so I can’t open pop tops on cans or play the guitar anymore. I also can’t taste salt and the nails on my fingers and toes lift off.

I don’t dwell on the negatives; I continue to live my life as well as I can. I go to work every day, my wife and I started a new business, and I schedule competing in clay pigeon shooting tournaments months in advance.

Before my diagnosis, I had barely even heard of bladder cancer, but it is the sixth most common cancer diagnosed in the United States. I hope that by sharing my experience I can increase awareness about bladder cancer and the need for research funding.

Top of page

American Association for Cancer Research Foundation
The AACR Cancer Progress Report is published by the American Association for Cancer Research (AACR). The mission of the AACR is to prevent and cure cancer through research, education, communication, and collaboration.

Requests for permission to reuse or reprint any part of the Cancer Progress Report should be sent to permissions@aacr.org.

© 2018 AACR | 615 Chestnut Street, 17th Floor, Philadelphia, PA 19106
215-440-9300 | aacr@aacr.org

The American Association for Cancer Research (AACR) is a 501(c)(3) registered nonprofit organization (23-6251648).
Other AACR Sites
AACR Website
AACR Foundation Website
Cancer Today Magazine
AACR Blog: Cancer Research Catalyst

Follow the AACR


Follow the AACR Foundation